Leinco Technologies, Inc.
Fenton, MO Doing business as Leinco Technologies Inc.
- UEI
- G7GHZKCJWDE3
- CAGE
- 5AHK0
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 410 Axminister Dr, Fenton, MO 63026, USA
- Website
- leinco.com
- Founded
- 1992
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Laboratory testing | National Cancer Institute | $14,800 | |
| Monoclonal antibodies from knockout mice who have been in-vivo genetically immunized with interferon-alpha/beta receptor… | Defense Health Agency | $33,125 | |
| Monoclonal antibodies from knockout mice who have been in-vivo genetically immunized with interferon-alpha/beta receptor… | Defense Health Agency | $34,225 | |
| Covid 19 research anti-mouse ifnar-1-purified in vivo goldtm functional grade (clone: MAR1-5A3) | National Institute of Allergy and Infectious Diseases | $11,560 | |
| Anti-mouse IFNAR1 purified functional grade, gold i-401 (100 MG) | National Institute of Allergy and Infectious Diseases | $4,110 |
About Leinco Technologies, Inc.
Leinco Technologies, Inc. is a self-certified small disadvantaged business and manufacturer of goods located in Fenton, Missouri, registered in SAM.gov since 2009. The company specializes in producing high-quality biological research materials, with a particular focus on monoclonal antibodies and laboratory testing services for scientific and medical research. As a for-profit corporate entity, Leinco Technologies has positioned itself as a critical supplier of specialized biological products to federal research agencies, demonstrating expertise in immunology and infectious disease research.
The company has consistently secured federal contract awards primarily from the National Cancer Institute and the Defense Health Agency, focusing on providing specialized antibodies and laboratory testing services. Leinco Technologies has been instrumental in supporting COVID-19 and viral research efforts, delivering monoclonal antibodies derived from genetically immunized knockout mice and producing critical research materials. The company has worked as both a prime contractor and subcontractor, notably collaborating with Battelle Memorial Institute on SARS-CoV-1 and SARS-CoV-2 research. Its federal contract awards have ranged from $11,560 to $34,225, covering specific research-oriented purchase orders and delivery orders that support viral pathogen research. None of these contracts utilized set-aside designations, indicating the company's competitive positioning in the federal marketplace.
Leinco Technologies has secured an Indefinite Delivery Contract (IDC) with the Defense Health Agency, awarded on August 23, 2024, with a total ceiling value of $650,000 and a performance period extending through September 2, 2029. This single-award IDC is specifically designed for the delivery of monoclonal antibodies to meet the agency's material requirements. The contract underscores the company's ongoing capabilities in supplying specialized biological products, particularly in the domains of immunology and infectious disease research. By obtaining this long-term contract vehicle, Leinco Technologies has established a strategic framework for continued engagement with the Defense Health Agency, positioning itself as a reliable provider of critical research materials and antibody products for federal scientific initiatives.
SBA capabilities narrative
Manufacturing of antibodies that specifically bind to intracellular antigens or cell surface receptors. We also off Low Endotoxin Functional Monoclonal Antibodies for applications such as flow cytometry, ELISA, Western blotting and microscopy.
Quick answers
What is Leinco Technologies, Inc.'s UEI?
Leinco Technologies, Inc.'s Unique Entity ID (UEI) in SAM.gov is G7GHZKCJWDE3.
What is Leinco Technologies, Inc.'s CAGE code?
Leinco Technologies, Inc.'s CAGE code is 5AHK0.
What is Leinco Technologies, Inc.'s primary NAICS code?
Leinco Technologies, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Leinco Technologies, Inc. located?
Leinco Technologies, Inc.'s physical address in SAM.gov is 410 Axminister Dr, Fenton, MO 63026, USA.
Is Leinco Technologies, Inc. registered in SAM.gov?
Yes. Leinco Technologies, Inc.'s SAM.gov registration is active through February 5, 2027.
What is Leinco Technologies, Inc.'s most recent federal award?
Leinco Technologies, Inc.'s most recent federal contract award is Laboratory testing (75N91025P00119), from National Cancer Institute, on December 28, 2024.
On GovTribe
See Leinco Technologies, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors